Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:1511-1520
Published online before print April 26, 2007, doi: 10.1161/ATVBAHA.107.141390
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/7/1511    most recent
ATVBAHA.107.141390v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Andrews, R. K.
Right arrow Articles by Berndt, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Andrews, R. K.
Right arrow Articles by Berndt, M. C.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:1511.)
© 2007 American Heart Association, Inc.


Brief Reviews

Platelet Receptor Proteolysis

A Mechanism for Downregulating Platelet Reactivity

Robert K. Andrews; Denuja Karunakaran; Elizabeth E. Gardiner; Michael C. Berndt

From the Departments of Immunology (R.K.A., E.E.G., M.C.B.) and Biochemistry and Molecular Biology (D.K.), Monash University, Melbourne, Australia.

Correspondence to Robert K. Andrews or Michael C. Berndt, Department of Immunology, Monash University, Alfred Medical Research & Education Precinct (AMREP), Melbourne 3004, Australia. E-mail rob.andrews{at}med.monash.edu.au or michael.berndt@med.monash.edu.au

The platelet plasma membrane is literally at the cutting-edge of recent research into proteolytic regulation of the function and surface expression of platelet receptors, revealing new mechanisms for how the thrombotic propensity of platelets is controlled in health and disease. Extracellular proteolysis of receptors irreversibly inactivates receptor-mediated adhesion and signaling, as well as releasing soluble fragments into the plasma where they act as potential markers or modulators. Platelet-surface sheddases, particularly of the metalloproteinase-disintegrin (ADAM) family, can be regulated by many of the same mechanisms that control receptor function, such as calmodulin association or activation of signaling pathways. This provides layers of regulation (proteinase and receptor), and a higher order of control of cellular function. Activation of pathways leading to extracellular shedding is concomitant with activation of intracellular proteinases such as calpain, which may also irreversibly deactivate receptors. In this review, platelet receptor shedding will be discussed in terms of (1) the identity of proteinases involved in receptor proteolysis, (2) key platelet receptors regulated by proteolytic pathways, and (3) how shedding might be regulated in normal physiology or future therapeutics. In particular, a focus on proteolytic regulation of the platelet collagen receptor, glycoprotein (GP)VI, illustrates many of the key biochemical, cellular, and clinical implications of current research in this area.

This review focuses on key proteolytic mechanisms regulating the surface expression, adheso-signaling function and plasma levels of platelet receptors involved in thrombosis, inflammation and other vascular processes, in particular using platelet collagen receptor, glycoprotein (GP)VI, shedding to illustrate the implications for normal physiology or future therapeutics.


Key Words: glycoprotein Ib-IX-V • glycoprotein VI • platelets • thrombosis • shedding




This article has been cited by other articles:


Home page
GutHome page
L Menchen, I Marin-Jimenez, E G Arias-Salgado, T Fontela, P Hernandez-Sampelayo, M C G. Rodriguez, and N V Butta
Matrix metalloproteinase 9 is involved in Crohn's disease-associated platelet hyperactivation through the release of soluble CD40 ligand
Gut, July 1, 2009; 58(7): 920 - 928.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
J. Rivera, M. L. Lozano, L. Navarro-Nunez, and V. Vicente
Platelet receptors and signaling in the dynamics of thrombus formation
Haematologica, May 1, 2009; 94(5): 700 - 711.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
J. Wacker, E. Lucchinetti, M. Jamnicki, J. Aguirre, L. Harter, M. Keel, and M. Zaugg
Delayed Inhibition of Agonist-Induced Granulocyte-Platelet Aggregation After Low-Dose Sevoflurane Inhalation in Humans
Anesth. Analg., June 1, 2008; 106(6): 1749 - 1758.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
L. F. Brass, L. Zhu, and T. J. Stalker
Novel Therapeutic Targets at the Platelet Vascular Interface
Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): s43 - s50.
[Abstract] [Full Text] [PDF]